Payment overview · 2025
General Payments
$262,847.45
432 reported records · 26 companies
Healthcare provider profile · identity verified
Vamsi Krishna, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · KYLE, TX · NPI 1891930863
Verified facts
What the public records show
CMS Open Payments records show Vamsi Krishna, M.D. received $262,847.45 in general payments during 2025 across 432 reported records.
Shockwave Medical, Inc accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Furoscix, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Wegovy by this doctor in 2024.
SCPHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FUROSCIX as an associated drug or biological on 18968 records involving 9678 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Furoscix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $84,394.72 | 32.1% | 59 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77,366.03 | 29.4% | 82 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50,092.32 | 19.1% | 54 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18,354.82 | 7.0% | 25 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $8,944.15 | 3.4% | 53 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $8,486.17 | 3.2% | 13 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $4,561.04 | 1.7% | 30 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,937.32 | 1.5% | 19 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $2,328.54 | 0.9% | 13 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $1,566.95 | 0.6% | 10 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $586.12 | 0.2% | 9 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $455.59 | 0.2% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$334.34 | 0.1% | 6 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $226.22 | 0.1% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $210.94 | 0.1% | 14 | 2025 |
| Baylis Medical Technologies Inc. | Unresolved — no canonical attribution shown | $200.09 | 0.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $187.56 | 0.1% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $140.72 | 0.1% | 10 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $100.35 | 0.0% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $95.41 | 0.0% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $94.98 | 0.0% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $73.85 | 0.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $39.22 | 0.0% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $32.92 | 0.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.33 | 0.0% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $14.75 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125,423.37 | 52 |
| Consulting Fee | $82,800.00 | 25 |
| Travel and Lodging | $25,107.75 | 66 |
| Honoraria | $15,750.00 | 5 |
| Food and Beverage | $13,766.33 | 284 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $84,394.72 | 59 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73,929.38 | 76 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45,925.56 | 51 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $18,354.82 | 25 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $8,486.17 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $3,937.32 | 19 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $3,576.72 | 16 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $3,379.58 | 5 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $3,300.00 | 2 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $1,615.20 | 11 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $1,615.20 | 11 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $1,126.08 | 18 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | BIOTRONIK INC., Teleflex LLC | $726.71 | 14 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $686.15 | 11 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $484.68 | 10 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $413.33 | 10 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $348.68 | 7 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $226.22 | 5 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $206.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $192.61 | 13 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $180.45 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $153.89 | 4 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $109.79 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $104.14 | 3 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $100.35 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $94.98 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $94.19 | 6 | 2025 |
Source payment records
|
|||||
| PANTERA LEO Normalized: pantera leo |
Device | Teleflex LLC | $92.97 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $83.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.89 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $46.53 | 4 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $43.81 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| REVCORE THROMBECTOMY CATHETER Normalized: revcore thrombectomy catheter |
Device | Stryker Corporation | $32.04 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| NHancer Rx Normalized: nhancer rx |
Device | BIOTRONIK INC. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $3.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 180 | exact normalized | Medicare Part D |
| FUROSCIX furoscix |
2025 | Furoscix | 2024 | 26 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 241 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
149 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
180 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
241 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| SCPHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | FUROSCIX open payments reported associated product |
CMS Open Payments — General Payments 18968 supporting records · 9678 recipient NPIs · example record 1228171755 |
Furoscix · 2024 Exact normalized brand match · 1 Part D row |
26 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1081 | 344 |
| Ezetimibe | Ezetimibe | 893 | 280 |
| Clopidogrel | Clopidogrel Bisulfate | 482 | 162 |
| Xarelto | Rivaroxaban | 344 | 87 |
| Carvedilol | Carvedilol | 321 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 89 |
| Furosemide | Furosemide | 257 | 106 |
| Repatha Sureclick | Evolocumab | 248 | 85 |
| Ozempic | Semaglutide | 241 | 72 |
| Losartan Potassium | Losartan Potassium | 238 | 76 |
| Potassium Chloride | Potassium Chloride | 229 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 77 |
| Repatha Pushtronex | Evolocumab | 183 | 67 |
| Entresto | Sacubitril/Valsartan | 180 | 48 |
| Eliquis | Apixaban | 169 | 51 |
| Mounjaro | Tirzepatide | 149 | 26 |
| Prasugrel Hcl | Prasugrel Hcl | 145 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 35 |
| Lisinopril | Lisinopril | 107 | 36 |
| Farxiga | Dapagliflozin Propanediol | 98 | 25 |
| Colchicine | Colchicine | 72 | 24 |
| Vascepa | Icosapent Ethyl | 71 | 18 |
| Ranolazine Er | Ranolazine | 68 | 22 |
| Brilinta | Ticagrelor | 67 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 23 |
| Jardiance | Empagliflozin | 55 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 18 |
| Telmisartan | Telmisartan | 43 | 14 |
| Praluent Pen | Alirocumab | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 37 | 14 |
| Irbesartan | Irbesartan | 36 | 11 |
| Spironolactone | Spironolactone | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Torsemide | Torsemide | 30 | 12 |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Wegovy | Semaglutide | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Furoscix | Furosemide | 26 | 20 |
| Valsartan | Valsartan | 24 | suppressed |
| Nifedipine Er | Nifedipine | 22 | 13 |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Gabapentin | Gabapentin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $262,847.45 · 432 records | Shockwave Medical, Inc | ABRE, AFREZZA, ARTIX MT, Assure WCD, CAMZYOS, CARDIOMEMS, CARTO 3, COROFLOW, CT THROMBECTOMY SYSTEM KIT, Coronary Other, Coronary Undivided, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ELIQUIS, ENROUTE Transcarotid Neuroprotection System, ENTRESTO, FFRct, FLOWTRIEVER CATHETER, S, FUROSCIX, General - Vascular Intervention, IGT Devices Undivided, IV Other, Indigo System, LEQVIO, LOKELMA, Labosys, MANTA, MOUNJARO, NHancer Rx, OPTIS, ORSIRO MISSION, Ozempic, PANTERA LEO, PRESSUREWIRE, REPATHA, REVCORE THROMBECTOMY CATHETER, ROSEN, RotarexS 6 F x 135 cm, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TACTICATH ABLATION CATHETER, SENSOR ENABLED, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error